Evidence map›Paper›PMID 24888810›Full record

Trial reportJournal of clinical oncology : official journal of the American Society of Clinical Oncology2014

Randomized, phase III trial of first-line figitumumab in combination with paclitaxel and carboplatin versus paclitaxel and carboplatin alone in patients with advanced non-small-cell lung cancer.

Corey J Langer, Silvia Novello, Keunchil Park, Maciej Krzakowski, Daniel D Karp, Tony Mok, Rebecca J Benner, Judith R Scranton, Anthony J Olszanski, Jacek Jassem

Open access · greenAbstract readClinical Trial, Phase IIIRandomized Controlled Trial
PubMed Full text at PMC Publisher
In one paragraph

Trial report in Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 129 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
129citing papers in PubMed, 2 pooled it
10.5field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

129 citing papers in PubMed, 2 syntheses or guidelines pooled it, 179 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Trial
  4. Trial
  5. Trial
  6. Trial
  7. Trial
  8. Trial
  9. Randomized Phase II Trial of Seribantumab in Combination With Paclitaxel in Patients With Advanced Platinum-Resistant or -Refractory Ovarian Cancer.Journal of clinical oncology : official journal of the American Society of Clinical Oncology · 2016
    Trial
  10. Trial
  11. Lung Master Protocol (Lung-MAP)-A Biomarker-Driven Protocol for Accelerating Development of Therapies for Squamous Cell Lung Cancer: SWOG S1400.Clinical cancer research : an official journal of the American Association for Cancer Research · 2015
    Trial
  12. Trial
  13. Insulin-like growth factor receptor signaling in physiology and disease.Signal transduction and targeted therapy · 2026
    Review
  14. Review
  15. Review
  16. Article
  17. Article
  18. Article
  19. IGF1R signaling induces epithelial-mesenchymal plasticity via ITGAV in cutaneous carcinoma.Journal of experimental & clinical cancer research : CR · 2024
    Article
  20. Structural Models for a Series of Allosteric Inhibitors of IGF1R Kinase.International journal of molecular sciences · 2024
    Article

69 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Corey J LangerCorey J. Langer, University of Pennsylvania; Anthony J. Olszanski, Fox Chase Cancer Center, Philadelphia, PA; Daniel D. Karp, MD Anderson Center, Houston, TX; Rebecca J. Benner, Judith R. Scranton, Pfizer Oncology, Groton, CT; Silvia Novello, University of Turin, Orbassano, Italy; Keunchil Park, Sungkyunkwan University School of Medicine, Seoul, Korea; Maciej Krzakowski, The Maria Sklodowska-Curie Institute of Oncology, Warsaw; Jacek Jassem, Medical University of Gdansk, Gdansk, Poland; Tony Mok, Chinese University, Hong Kong, Special Administrative Region, People's Republic of China. corey.langer@uphs.upenn.edu.
Silvia NovelloCorey J. Langer, University of Pennsylvania; Anthony J. Olszanski, Fox Chase Cancer Center, Philadelphia, PA; Daniel D. Karp, MD Anderson Center, Houston, TX; Rebecca J. Benner, Judith R. Scranton, Pfizer Oncology, Groton, CT; Silvia Novello, University of Turin, Orbassano, Italy; Keunchil Park, Sungkyunkwan University School of Medicine, Seoul, Korea; Maciej Krzakowski, The Maria Sklodowska-Curie Institute of Oncology, Warsaw; Jacek Jassem, Medical University of Gdansk, Gdansk, Poland; Tony Mok, Chinese University, Hong Kong, Special Administrative Region, People's Republic of China.
Keunchil ParkCorey J. Langer, University of Pennsylvania; Anthony J. Olszanski, Fox Chase Cancer Center, Philadelphia, PA; Daniel D. Karp, MD Anderson Center, Houston, TX; Rebecca J. Benner, Judith R. Scranton, Pfizer Oncology, Groton, CT; Silvia Novello, University of Turin, Orbassano, Italy; Keunchil Park, Sungkyunkwan University School of Medicine, Seoul, Korea; Maciej Krzakowski, The Maria Sklodowska-Curie Institute of Oncology, Warsaw; Jacek Jassem, Medical University of Gdansk, Gdansk, Poland; Tony Mok, Chinese University, Hong Kong, Special Administrative Region, People's Republic of China.
Maciej KrzakowskiCorey J. Langer, University of Pennsylvania; Anthony J. Olszanski, Fox Chase Cancer Center, Philadelphia, PA; Daniel D. Karp, MD Anderson Center, Houston, TX; Rebecca J. Benner, Judith R. Scranton, Pfizer Oncology, Groton, CT; Silvia Novello, University of Turin, Orbassano, Italy; Keunchil Park, Sungkyunkwan University School of Medicine, Seoul, Korea; Maciej Krzakowski, The Maria Sklodowska-Curie Institute of Oncology, Warsaw; Jacek Jassem, Medical University of Gdansk, Gdansk, Poland; Tony Mok, Chinese University, Hong Kong, Special Administrative Region, People's Republic of China.
Daniel D KarpCorey J. Langer, University of Pennsylvania; Anthony J. Olszanski, Fox Chase Cancer Center, Philadelphia, PA; Daniel D. Karp, MD Anderson Center, Houston, TX; Rebecca J. Benner, Judith R. Scranton, Pfizer Oncology, Groton, CT; Silvia Novello, University of Turin, Orbassano, Italy; Keunchil Park, Sungkyunkwan University School of Medicine, Seoul, Korea; Maciej Krzakowski, The Maria Sklodowska-Curie Institute of Oncology, Warsaw; Jacek Jassem, Medical University of Gdansk, Gdansk, Poland; Tony Mok, Chinese University, Hong Kong, Special Administrative Region, People's Republic of China.
Tony MokCorey J. Langer, University of Pennsylvania; Anthony J. Olszanski, Fox Chase Cancer Center, Philadelphia, PA; Daniel D. Karp, MD Anderson Center, Houston, TX; Rebecca J. Benner, Judith R. Scranton, Pfizer Oncology, Groton, CT; Silvia Novello, University of Turin, Orbassano, Italy; Keunchil Park, Sungkyunkwan University School of Medicine, Seoul, Korea; Maciej Krzakowski, The Maria Sklodowska-Curie Institute of Oncology, Warsaw; Jacek Jassem, Medical University of Gdansk, Gdansk, Poland; Tony Mok, Chinese University, Hong Kong, Special Administrative Region, People's Republic of China.
Rebecca J BennerCorey J. Langer, University of Pennsylvania; Anthony J. Olszanski, Fox Chase Cancer Center, Philadelphia, PA; Daniel D. Karp, MD Anderson Center, Houston, TX; Rebecca J. Benner, Judith R. Scranton, Pfizer Oncology, Groton, CT; Silvia Novello, University of Turin, Orbassano, Italy; Keunchil Park, Sungkyunkwan University School of Medicine, Seoul, Korea; Maciej Krzakowski, The Maria Sklodowska-Curie Institute of Oncology, Warsaw; Jacek Jassem, Medical University of Gdansk, Gdansk, Poland; Tony Mok, Chinese University, Hong Kong, Special Administrative Region, People's Republic of China.
Judith R ScrantonCorey J. Langer, University of Pennsylvania; Anthony J. Olszanski, Fox Chase Cancer Center, Philadelphia, PA; Daniel D. Karp, MD Anderson Center, Houston, TX; Rebecca J. Benner, Judith R. Scranton, Pfizer Oncology, Groton, CT; Silvia Novello, University of Turin, Orbassano, Italy; Keunchil Park, Sungkyunkwan University School of Medicine, Seoul, Korea; Maciej Krzakowski, The Maria Sklodowska-Curie Institute of Oncology, Warsaw; Jacek Jassem, Medical University of Gdansk, Gdansk, Poland; Tony Mok, Chinese University, Hong Kong, Special Administrative Region, People's Republic of China.
Anthony J OlszanskiCorey J. Langer, University of Pennsylvania; Anthony J. Olszanski, Fox Chase Cancer Center, Philadelphia, PA; Daniel D. Karp, MD Anderson Center, Houston, TX; Rebecca J. Benner, Judith R. Scranton, Pfizer Oncology, Groton, CT; Silvia Novello, University of Turin, Orbassano, Italy; Keunchil Park, Sungkyunkwan University School of Medicine, Seoul, Korea; Maciej Krzakowski, The Maria Sklodowska-Curie Institute of Oncology, Warsaw; Jacek Jassem, Medical University of Gdansk, Gdansk, Poland; Tony Mok, Chinese University, Hong Kong, Special Administrative Region, People's Republic of China.
Jacek JassemCorey J. Langer, University of Pennsylvania; Anthony J. Olszanski, Fox Chase Cancer Center, Philadelphia, PA; Daniel D. Karp, MD Anderson Center, Houston, TX; Rebecca J. Benner, Judith R. Scranton, Pfizer Oncology, Groton, CT; Silvia Novello, University of Turin, Orbassano, Italy; Keunchil Park, Sungkyunkwan University School of Medicine, Seoul, Korea; Maciej Krzakowski, The Maria Sklodowska-Curie Institute of Oncology, Warsaw; Jacek Jassem, Medical University of Gdansk, Gdansk, Poland; Tony Mok, Chinese University, Hong Kong, Special Administrative Region, People's Republic of China.

Funding

Tumor Evolution and Metastasis ProgramP30CA016672 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI Scott Kopetz · 1985 to 2026
$290.8M
Center for Clinical and Translational Sciences (CCTS)UL1TR000371 · NCATS · UNIVERSITY OF TEXAS HLTH SCI CTR HOUSTON · PI MCPHERSON, DAVID D · 2012 to 2016
$13.4M
NCATS NIH HHS UL1 TR000371NCI NIH HHS CA16672NCI NIH HHS P30 CA016672
6 · The paper itself

Abstract

purposeFigitumumab (CP-751,871), a fully human immunoglobulin G2 monoclonal antibody, inhibits the insulin-like growth factor 1 receptor (IGF-1R). Our multicenter, randomized, phase III study compared figitumumab plus chemotherapy with chemotherapy alone as first-line treatment in patients with advanced non-small-cell lung cancer (NSCLC). PATIENTS AND

methodsPatients with stage IIIB/IV or recurrent NSCLC disease with nonadenocarcinoma histology received open-label figitumumab (20 mg/kg) plus paclitaxel (200 mg/m(2)) and carboplatin (area under the concentration-time curve, 6 mg · min/mL) or paclitaxel and carboplatin alone once every 3 weeks for up to six cycles. The primary end point was overall survival (OS).

resultsOf 681 randomly assigned patients, 671 received treatment. The study was closed early by an independent Data Safety Monitoring Committee because of futility and an increased incidence of serious adverse events (SAEs) and treatment-related deaths with figitumumab. Median OS was 8.6 months for figitumumab plus chemotherapy and 9.8 months for chemotherapy alone (hazard ratio [HR], 1.18; 95% CI, 0.99 to 1.40; P = .06); median progression-free survival was 4.7 months (95% CI, 4.2 to 5.4) and 4.6 months (95% CI, 4.2 to 5.4), respectively (HR, 1.10; P = .27); the objective response rates were 33% and 35%, respectively. The respective rates of all-causality SAEs were 66% and 51%; P < .01). Treatment-related grade 5 adverse events were also more common with figitumumab (5% v 1%; P < .01).

conclusionAdding figitumumab to standard chemotherapy failed to increase OS in patients with advanced nonadenocarcinoma NSCLC. Further clinical development of figitumumab is not being pursued.

Indexed as

AdultAgedAntibodies, MonoclonalAntineoplastic Combined Chemotherapy ProtocolsCarboplatinCarcinoma, Non-Small-Cell LungDisease-Free SurvivalDrug Administration ScheduleFemaleGlycated HemoglobinHumansInsulin-Like Growth Factor IKaplan-Meier EstimateLung NeoplasmsMaleMiddle AgedAntibodies, MonoclonalCarboplatinfigitumumabGlycated Hemoglobinhemoglobin A1c protein, humanInsulin-Like Growth Factor IPaclitaxel

Identifiers

PMID24888810
PMCPMC4067944
OpenAlexW2108949840

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.